Investors

SEC Filings

SEC Filings

Filing date	Form	Description	View
March 31, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001193125-23-088046.pdf 0001193125-23-088046.rtf View HTML
April 11, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001193125-23-097795.pdf 0001193125-23-097795.rtf View HTML
April 14, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001193125-23-101547.pdf 0001193125-23-101547.rtf View HTML
April 14, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001193125-23-102245.pdf 0001193125-23-102245.rtf View HTML
April 21, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001193125-23-110580.pdf 0001193125-23-110580.rtf View HTML
March 17, 2023	DEFR14A	DEFR14A	0001193125-23-073252.pdf 0001193125-23-073252.rtf 0001193125-23-073252.xls View HTML
December 20, 2013	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-13-010530.pdf 0000950123-13-010530.rtf 0000950123-13-010530.xls View HTML
January 27, 2014	DRS/A	mendment to a previously filed DRS	0000950123-14-000635.pdf 0000950123-14-000635.rtf 0000950123-14-000635.xls View HTML
March 19, 2014	EFFECT	EFFECT	9999999995-14-000699.pdf 9999999995-14-000699.rtf 9999999995-14-000699.xls View HTML
April 14, 2015	EFFECT	EFFECT	9999999995-15-000874.pdf 9999999995-15-000874.rtf 9999999995-15-000874.xls View HTML

Data provided by Kaleidoscope.

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax